Scinai Immunotherapeutics Ltd
Scinai Immunotherapeutics Ltd., a biopharmaceutical company, focuses on developing, manufacturing, and commercializing inflammation and immunology biological products for the treatment of infectious and autoimmune diseases in Israel. It develops nanosized VHH antibodies (nanoAbs) targeting diseases with unmet medical needs; and PC111, a monoclonal antibody for treating pemphigus, steven johnson's… Read more
Scinai Immunotherapeutics Ltd (SCNI) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: -0.164x
Based on the latest financial reports, Scinai Immunotherapeutics Ltd (SCNI) has a cash flow conversion efficiency ratio of -0.164x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.29 Million) by net assets ($7.86 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Scinai Immunotherapeutics Ltd - Cash Flow Conversion Efficiency Trend (2006–2024)
This chart illustrates how Scinai Immunotherapeutics Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Scinai Immunotherapeutics Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Scinai Immunotherapeutics Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
GREEN SHIFT COMMODITIES
F:7WV
|
N/A |
|
Mekong Fisheries JSC
VN:AAM
|
N/A |
|
Bounty Oil & Gas NL
PINK:BYOGF
|
-0.011x |
|
Canlan Ice Sports Corp
PINK:CNLFF
|
0.085x |
|
Awakn Life Sciences Corp
PINK:AWKNF
|
0.391x |
|
THALES - Dusseldorf Stock Exchang
DU:CSF
|
N/A |
|
Simble Solutions Ltd
AU:SIS
|
1.447x |
|
Sadot Group Inc.
NASDAQ:SDOT
|
-0.084x |
Annual Cash Flow Conversion Efficiency for Scinai Immunotherapeutics Ltd (2006–2024)
The table below shows the annual cash flow conversion efficiency of Scinai Immunotherapeutics Ltd from 2006 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $9.98 Million | $-6.33 Million | -0.635x | -130.92% |
| 2023-12-31 | $-4.57 Million | $-9.38 Million | 2.053x | -50.25% |
| 2022-12-31 | $-1.76 Million | $-7.26 Million | 4.128x | +154.59% |
| 2021-12-31 | $982.00K | $-7.43 Million | -7.562x | -252.16% |
| 2020-12-31 | $-4.54 Million | $-22.57 Million | 4.970x | +319.55% |
| 2019-12-31 | $-18.84 Million | $-22.31 Million | 1.185x | -35.35% |
| 2018-12-31 | $-8.35 Million | $-15.29 Million | 1.832x | +1125.54% |
| 2017-12-31 | $16.17 Million | $-2.89 Million | -0.179x | +52.59% |
| 2016-12-31 | $6.65 Million | $-2.51 Million | -0.377x | -23.12% |
| 2015-12-31 | $8.61 Million | $-2.63 Million | -0.306x | +32.95% |
| 2014-12-31 | $4.26 Million | $-1.94 Million | -0.457x | -160.40% |
| 2013-12-31 | $6.92 Million | $-1.21 Million | -0.175x | +42.74% |
| 2012-12-31 | $5.95 Million | $-1.82 Million | -0.306x | +24.07% |
| 2011-12-31 | $6.71 Million | $-2.71 Million | -0.403x | -39.67% |
| 2010-12-31 | $7.94 Million | $-2.29 Million | -0.289x | -185.60% |
| 2009-12-31 | $8.44 Million | $-852.95K | -0.101x | -1862.97% |
| 2006-12-31 | $1.74 Million | $10.00K | 0.006x | -- |